QUEST DIAGNOSTICS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.2 USD | +0.42% |
|
+2.95% | +3.19% |
Financials (USD)
| Sales 2024 * | 9.45B | Sales 2025 * | 9.76B | Capitalization | 15.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 897M | Net income 2025 * | 971M | EV / Sales 2024 * | 2.09 x |
| Net Debt 2024 * | 4.04B | Net Debt 2025 * | 3.56B | EV / Sales 2025 * | 1.97 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
16.6
x | Employees | 44,000 |
| Yield 2024 * |
2.08% | Yield 2025 * |
2.1% | Free-Float | 68.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | +0.41% | ||
| 1 week | +3.21% | ||
| Current month | +0.46% | ||
| 1 month | +5.15% | ||
| 3 months | +14.55% | ||
| 6 months | +5.74% | ||
| Current year | +3.45% |
1 week
137.36
142.98
1 month
135.35145.62
Current year
123.04145.62
1 year
119.59145.62
3 years
119.59174.16
5 years
73.02174.16
10 years
56.27174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 66 | 11-12-06 |
Gary Pfeiffer
BRD | Director/Board Member | 74 | 04-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 254 M€ | +13.07% | - | |
| 2.17% | 2 M€ | +9.08% | ||
| 2.05% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 142.2 | +0.45% | 392 989 |
| 24-06-04 | 141.6 | +0.33% | 818,752 |
| 24-06-03 | 141.1 | -0.61% | 634,334 |
| 24-05-31 | 142 | +1.89% | 2,238,021 |
| 24-05-30 | 139.3 | +0.82% | 838,572 |
Delayed Quote Nyse, June 05, 2024 at 01:32 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-07-07
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
141.6
USD
Average target price
147
USD
Spread / Average Target
+3.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.45% | 15.73B | |
| +23.75% | 86.96B | |
| -23.44% | 75.65B | |
| +0.49% | 26.97B | |
| +5.59% | 17.89B | |
| -12.65% | 16.58B | |
| +78.69% | 13.01B | |
| +80.32% | 12.92B | |
| +37.63% | 12.57B | |
| +3.19% | 12.5B |
- Stock Market
- Equities
- DGX Stock
